

February 21, 2025

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
The Manager – Listing,  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sirs,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 – Intimation of Investors/Analyst Meeting**

With reference to the captioned subject and pursuant to Regulation 30 and Para A of Part A of Schedule III of SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, please find below details of the meetings with Investor/Analyst which will be attended by the representatives of the Company:

Date	Name	Mode	Place	Type of Meeting
February 27, 2025	Polar Capital	In-Person	Mumbai	One on One

The schedule and mode of meeting may undergo a change due to exigencies on part of the Investor/Analyst/Company.

You are requested to kindly take a note of the same.

Thanking You,

Your Sincerely,

**For Alivus Life Sciences Limited**

(formerly known as Glenmark Life Sciences Limited)

**Rudalf Corriea**

**Company Secretary & Compliance officer**

**Alivus Life Sciences Limited** (formerly Glenmark Life Sciences Limited)

**Corporate Office:**

4th Floor, OIA House, 470, Cardinal Gracious Road  
Andheri (E), Mumbai 400 099, Maharashtra, India

**Registered Office:**

Plot No 170-172, Chandramouli Industrial Estate  
Mohol Bazarpath, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: complianceofficer@glenmarklifesciences.com | W: www.alivus.com

